Impairment of lymphocyte function following yttrium-90 DOTATOC therapy

Abstract

The radiolabeled somatostatin analogue, yttrium-90 DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC), is currently applied to treat advanced somatostatin receptor-positive tumors, e.g., neuroendocrine tumors of the pancreas, lung or gut. However, effects of this treatment on antimicrobial immune responses are not yet defined. In 20 patients treated with DOTATOC, cellular in vitro immune function was determined. Their antimicrobial lymphocyte responses were assessed by lymphocyte transformation test and enzyme-linked immunospot-measuring lymphocyte proliferation and on a single cell level production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10)-prior to therapy, at day 1, day 7 and day 90 post-therapy. Proliferative lymphocyte responses and interferon-γ production after in vitro stimulation with microbial antigens were non-significantly suppressed at day 1 and significantly (p < 0.05) at day 7 versus pre-therapy. In vitro immune responses did not fully recover until day 90. In contrast, at day 1 interleukin-10 production was significantly (p < 0.05) increased. Taken together, we observed a decrease in pro-inflammatory immune responses after DOTATOC therapy. Patients with versus without bone metastases displayed significantly (p < 0.05) lower cellular immune responses toward several microbial antigens. Progressive disease and higher tumor burden could also be defined as factors associated with impaired immune function. Spearman correlation analysis indicated that cellular in vitro immunity was positively correlated with kidney function; better kidney function led to stronger immune responses. In conclusion, DOTATOC therapy caused a decrease in in vitro immune responses against microorganisms. The clinical impact needs to be evaluated in further studies.

Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells

“…Firstly, the SSTR2 receptor internalizes on interaction with its substrates, risking poor sensitivity, especially at lower reporter gene expressing cell density 32 . Secondly, SSTR2 is expressed on T cells and other immune cells 33 , accounting for the ability of octreotide analogs and their radiolabeled derivatives to inhibit T-cell function 34 . This is clearly undesirable for a broadly applicable strategy to image therapeutic T-cell products in cancer patients.…”

Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT)

“…Cancer treatment can also result in reduced lymphocyte growth . Yet, the numerous individual cancer‐related variables in the NSSP dataset (eg, histories of cancer in the lung, colon, breast, stomach, and skin) did not show a strong enough association with PG to be included in the final multivariable model.…”

Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line

“…To assess proliferation, the cultures were labeled for the final 16 hours with 37 MBq H3 thymidine per well (TRA.120, specific activity 5 Ci/mmol, GE Healthcare, Buckinghamshire, UK) [ 17 ]. The cultures were then harvested (Harvester 96, Tomtec, Hamden, CT, USA) onto filter pads (Wallac, Turku, Finland), and the incorporated radioactivity was quantified by liquid scintillation counting (1450 Microbeta Trilux, Wallac).…”